Ascendis Pharma A/S ASND

Latest FY: 2025 Healthcare Biotechnology
Market Price $261.10
Market Cap $17.15B
P/E Ratio N/A
Quick Peer Compare (Healthcare):
Revenue (FY 2025) ↑98.0% YoY
$720.13M
3-Yr CAGR: 141.4%
Net Income ↑39.7% YoY
-$228.03M
Net Margin: -31.7%
Free Cash Flow ↓-135.9% YoY
-$1.81M
FCF Yield: -0.01%
EPS (Diluted)
N/A
Basic: N/A
Return on Equity Efficiency
N/A
ROA: -17.5%

📊 Multi-Year Historical Performance & Trends

Financial Performance History Revenue, Net Income & Free Cash Flow
Margins Trend (%) Gross, Operating & Net Margins
Balance Sheet Strength Cash, Debt & Equity
Cash Flow Generation Operating Cash Flow vs CapEx vs FCF

📈 Year-over-Year (YoY) Growth History (ASND)

All monetary values in millions ($M)
Fiscal Year Revenue Revenue YoY Gross Profit Net Income Net Inc YoY Diluted EPS EPS YoY Div / Sh Div Yield Op. Cash Flow Free Cash Flow FCF YoY
FY 2016 $4.6M $4.6M $-68.7M 0.00% $-0.6M
FY 2017 $1.5M -66.8% $1.4M $-124.4M -81.0% 0.00% $-0.2M $-1.1M
FY 2018 $10.6M +591.6% $10.5M $-130.5M -4.9% 0.00% $-0.3M $-3.0M -172.4%
FY 2019 $13.4M +26.4% $12.4M $-218.2M -67.3% 0.00% $0.3M $-4.9M -63.8%
FY 2020 $7.0M -48.0% $5.0M $-419.0M -92.0% 0.00% $-1.1M $-21.0M -329.4%
FY 2021 $7.8M +11.9% $4.3M $-383.6M +8.4% 0.00% $-0.2M $-23.9M -13.8%
FY 2022 $51.2M +557.9% $20.5M $-583.2M -52.0% 0.00% $0.0M $-5.0M +79.2%
FY 2023 $266.7M +421.2% $222.3M $-481.4M +17.4% 0.00% $4.5M $2.1M +141.9%
FY 2024 $363.6M +36.3% $298.1M $-378.1M +21.5% 0.00% $5.5M $5.0M +142.7%
FY 2025 $720.1M +98.0% $625.2M $-228.0M +39.7% 0.00% $6.7M $-1.8M -135.9%
$

Valuation

Market Price $261.10
Market Cap $17.15B
Enterprise Value N/A
P/E Ratio N/A
P/B Ratio N/A
FCF Yield -0.01%
Dividend Yield 0.00%
Shares Outstanding 65,673,300
%

Profitability & Margins

Gross Margin 86.82%
Operating Margin -18.92%
Net Margin -31.67%
Return on Equity (ROE) N/A
Return on Assets (ROA) -17.51%
Asset Turnover 0.55x
Revenue 3-Yr CAGR 141.43%
🛡️

Financial Health & Liquidity

Current Ratio N/A
Cash Ratio N/A
Debt / Equity N/A
Debt / Assets 0.000
Cash & Equivalents N/A
Total Debt N/A
Book Value / Share N/A
💧

Cash Flow Efficiency

Operating Cash Flow $6.68M
Capital Expenditures (CapEx) $8.48M
Free Cash Flow -$1.81M
OCF / Revenue 0.93%
FCF / Revenue -0.25%
FCF 3-Yr CAGR N/A
🏷️

Per Share Metrics

EPS (Diluted) N/A
EPS (Basic) N/A
Dividends / Share N/A
Book Value / Share N/A
EPS YoY Growth N/A
🏛️

Balance Sheet (FY 2025)

Total Assets $1.30B
Total Liabilities $1.47B
Stockholders' Equity N/A
Current Assets $1.78M
Current Liabilities N/A